name: CINCA Syndrome
category: Mendelian
synonyms:
  - Neonatal-onset multisystem inflammatory disease
  - NOMID
  - Chronic infantile neurological cutaneous and articular syndrome
  - CINCA/NOMID
  - Prieur-Griscelli syndrome
disease_term:
  preferred_term: CINCA syndrome
  term:
    id: MONDO:0011776
    label: CINCA syndrome
parents:
  - Autoinflammatory diseases
  - Cryopyrin-associated periodic syndromes
has_subtypes:
  - name: Classic CINCA with identifiable NLRP3 mutation
    description: >
      Patients with identifiable heterozygous gain-of-function mutations
      in NLRP3. Accounts for approximately 50-60% of clinically diagnosed
      CINCA/NOMID cases. Mutations are typically de novo.
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Gain-of-function mutations in NLRP3 in CAPS patients lead
          to activation of the cryopyrin inflammasome, resulting in the
          inappropriate release of inflammatory cytokines including IL-1beta
          and CAPS-related inflammatory symptoms."
        explanation: Review confirming NLRP3 gain-of-function mutations as
          the causative mechanism in CAPS including CINCA/NOMID.
  - name: Mutation-negative CINCA (somatic mosaicism)
    description: >
      Patients meeting clinical criteria for CINCA/NOMID but without
      detectable NLRP3 mutations by conventional sequencing. Many of
      these cases harbor somatic mosaicism for NLRP3 mutations detectable
      only by deep sequencing, with variant allele fractions as low as
      1.3%. Mosaicism may be myeloid-restricted or involve both myeloid
      and lymphoid lineages.
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We selected 18 patients with neonatal-onset multisystem
          inflammatory disease (12 with identifiable CIAS1 mutations) to
          receive anakinra, an interleukin-1-receptor antagonist"
        explanation: Landmark NEJM trial demonstrating that 6 of 18
          clinically definite NOMID patients lacked identifiable CIAS1
          mutations by standard sequencing, yet responded identically
          to IL-1 blockade, suggesting undetected somatic mosaicism.
      - reference: PMID:38720945
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Additional genetic investigations performed after
          the introduction of anti-IL-1 therapy revealed a pathogenic
          mosaicism in the NLRP3 gene."
        explanation: Case report demonstrating that initial NLRP3 testing
          was negative but subsequent deep sequencing revealed somatic
          mosaicism, underscoring the need for advanced sequencing in
          clinically diagnosed mutation-negative patients.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "approximately 28 ~ 35 % of all the CINCA/NOMID patients
          carry an NLRP3 mutation in somatic mosaicism state"
        explanation: Review of the literature quantifying the prevalence of
          somatic mosaicism in CINCA/NOMID, noting that mosaic patients
          tend to present with milder neurologic symptoms compared to
          those with germline mutations.
pathophysiology:
  - name: NLRP3 gain-of-function mutation
    description: >
      Heterozygous gain-of-function mutations in the NLRP3 gene (encoding
      cryopyrin) lower the activation threshold for NLRP3 inflammasome
      assembly. Most CINCA/NOMID mutations are de novo, arising
      post-zygotically or in the germline. The NLRP3 protein contains a
      pyrin domain, a NACHT domain, and leucine-rich repeats; disease
      mutations cluster in the NACHT domain and disrupt autoinhibitory
      conformations.
    downstream:
      - target: Constitutive NLRP3 inflammasome activation
    gene:
      preferred_term: NLRP3
      term:
        id: hgnc:16400
        label: NLRP3
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "This gene, called CIAS1, is expressed in peripheral blood
          leukocytes and encodes a protein with a pyrin domain, a
          nucleotide-binding site (NBS, NACHT subfamily) domain and a
          leucine-rich repeat (LRR) motif region, suggesting a role in the
          regulation of inflammation and apoptosis."
        explanation: Original identification of CIAS1/NLRP3 mutations as the
          cause of FCAS and MWS, establishing the genetic basis for the
          entire CAPS spectrum including CINCA/NOMID.
      - reference: DOI:10.1111/imr.13292
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Initially discovered as the cause of the autoinflammatory
          spectrum of cryopyrin-associated periodic syndrome (CAPS), NLRP3
          is now also known to play a role in more common diseases including
          cardiovascular disease, gout, and liver disease."
        explanation: Comprehensive review by Hoffman laboratory tracing the
          discovery of NLRP3 as the CAPS disease gene and its broader role
          in innate immunity.
  - name: Constitutive NLRP3 inflammasome activation
    description: >
      Mutant cryopyrin undergoes spontaneous oligomerization and
      constitutive assembly of the NLRP3 inflammasome complex, comprising
      NLRP3, ASC (PYCARD), and pro-caspase-1. NEK7 serves as a scaffold
      facilitating NLRP3 activation via microtubule organizing center
      trafficking. The resulting continuous activation of caspase-1
      occurs without normal requirement for exogenous danger signals.
      ASC speck formation, the hallmark of inflammasome assembly, is
      enhanced in patient myeloid cells and suppressible by MCC950.
    downstream:
      - target: Excessive IL-1beta production
      - target: Excessive IL-18 production
    biological_processes:
      - preferred_term: NLRP3 inflammasome complex assembly
        term:
          id: GO:0044546
          label: NLRP3 inflammasome complex assembly
        modifier: ABNORMAL
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Gain-of-function mutations in NLRP3 in CAPS patients lead
          to activation of the cryopyrin inflammasome, resulting in the
          inappropriate release of inflammatory cytokines including IL-1beta
          and CAPS-related inflammatory symptoms."
        explanation: Review describing constitutive inflammasome activation
          as the central pathogenic mechanism in CAPS, with gain-of-function
          mutations driving inappropriate caspase-1 activation and
          cytokine release.
      - reference: DOI:10.1111/imr.13292
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Activated by a panoply of pathogen-associated and
          endogenous triggers, NLRP3 serves as an intracellular sensor that
          drives carefully coordinated assembly of the inflammasome, and
          downstream inflammation mediated by IL-1 and IL-18."
        explanation: Review detailing normal and pathological NLRP3
          inflammasome assembly mechanisms, including ASC speck formation
          and regulatory nodes disrupted by CAPS mutations.
  - name: Excessive IL-1beta production
    description: >
      Constitutively active caspase-1 cleaves pro-IL-1beta into its
      mature, biologically active form. The resulting overproduction of
      IL-1beta is the primary driver of systemic inflammation, fever,
      and tissue damage throughout the body. Gasdermin D-dependent
      pyroptosis of activated myeloid cells releases intracellular
      contents including IL-1beta and amplifies inflammation.
    downstream:
      - target: Systemic neutrophilic inflammation
      - target: Central nervous system inflammation
      - target: Epiphyseal skeletal overgrowth
      - target: Cartilage damage and destructive arthropathy
      - target: Secondary amyloidosis
    biological_processes:
      - preferred_term: Positive regulation of interleukin-1 beta production
        term:
          id: GO:0032731
          label: positive regulation of interleukin-1 beta production
        modifier: ABNORMAL
      - preferred_term: Pyroptotic inflammatory response
        term:
          id: GO:0070269
          label: pyroptotic inflammatory response
        modifier: ABNORMAL
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Gain-of-function mutations in NLRP3 in CAPS patients lead
          to activation of the cryopyrin inflammasome, resulting in the
          inappropriate release of inflammatory cytokines including IL-1beta
          and CAPS-related inflammatory symptoms."
        explanation: Review confirming that excessive IL-1beta release from
          constitutively active inflammasome is the proximate cause of
          CAPS symptoms.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "These evidences suggest that foetal inflammation, probably
          due to overproduction of IL-1\u03b2, caused tissue damage in utero,
          and the first symptom of a newborn with CINCA/NOMID."
        explanation: Case report with histopathological evidence that
          IL-1beta overproduction begins in utero, causing necrotizing
          funisitis and villitis as the earliest manifestations of
          CINCA/NOMID even before birth.
      - reference: PMID:38808101
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Histopathologic examination of the placenta and umbilical
          cord can provide crucial insights into the intrauterine onset of
          inflammation, which is the first manifestation of CINCA
          syndrome/NOMID in newborns."
        explanation: Case report confirming intrauterine onset of
          IL-1beta-driven inflammation in CINCA/NOMID, with severe
          funisitis leading to umbilical cord rupture and neonatal
          asphyxia.
  - name: Excessive IL-18 production
    description: >
      Constitutively active caspase-1 also cleaves pro-IL-18 into its
      mature form. IL-18 contributes to macrophage activation and
      interferon-gamma production, amplifying the innate immune
      response and promoting Th1-polarized inflammation. Elevated
      serum IL-18 levels are a feature of CAPS and contribute to
      the systemic inflammatory burden alongside IL-1beta.
    downstream:
      - target: Systemic neutrophilic inflammation
    biological_processes:
      - preferred_term: Positive regulation of interleukin-18 production
        term:
          id: GO:0032741
          label: positive regulation of interleukin-18 production
        modifier: ABNORMAL
    evidence:
      - reference: DOI:10.1111/imr.13292
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Activated by a panoply of pathogen-associated and
          endogenous triggers, NLRP3 serves as an intracellular sensor that
          drives carefully coordinated assembly of the inflammasome, and
          downstream inflammation mediated by IL-1 and IL-18."
        explanation: Review identifying IL-18 alongside IL-1 as a key
          downstream inflammatory mediator of the NLRP3 inflammasome,
          confirming its role in CAPS pathogenesis.
  - name: Systemic neutrophilic inflammation
    description: >
      Excess IL-1beta drives recruitment and activation of neutrophils
      throughout the body, producing neutrophilic infiltration in skin,
      joints, meninges, and other tissues. The skin rash of CINCA is a
      neutrophilic urticarial dermatosis rather than true mast
      cell-mediated urticaria. Sustained neutrophilic inflammation causes
      tissue damage and organ dysfunction.
    locations:
      - preferred_term: Skin of body
        term:
          id: UBERON:0002097
          label: skin of body
    cell_types:
      - preferred_term: Neutrophil
        term:
          id: CL:0000775
          label: neutrophil
      - preferred_term: Monocyte
        term:
          id: CL:0000576
          label: monocyte
    biological_processes:
      - preferred_term: Neutrophil chemotaxis
        term:
          id: GO:0030593
          label: neutrophil chemotaxis
        modifier: ABNORMAL
      - preferred_term: Inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
        modifier: ABNORMAL
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: Landmark NEJM trial characterizing the multisystem
          neutrophilic inflammation in NOMID/CINCA affecting skin, CNS,
          joints, and sensory organs.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "the inflammation of the umbilical vessels typically begins
          in the vein (phlebitis) and is followed by involvement of the
          arteries (arteritis) and the Wharton's jelly"
        explanation: Histopathological evidence of neutrophilic infiltration
          in umbilical cord vessels and Wharton's jelly, demonstrating
          that neutrophilic inflammation begins in utero in CINCA/NOMID
          and can involve the placenta and umbilical cord.
  - name: Central nervous system inflammation
    description: >
      Chronic aseptic meningitis with neutrophilic and lymphocytic
      infiltration of the leptomeninges leads to elevated intracranial
      pressure, papilledema, progressive sensorineural hearing loss, and
      cognitive impairment. Microglial activation in the brain parenchyma
      may contribute to cerebral atrophy in inadequately treated patients.
      Cochlear inflammation produces progressive hearing loss, and
      leptomeningeal enhancement is visible on MRI.
    locations:
      - preferred_term: Leptomeninx
        term:
          id: UBERON:0000391
          label: leptomeninx
      - preferred_term: Cochlea
        term:
          id: UBERON:0001844
          label: cochlea
    cell_types:
      - preferred_term: Microglial cell
        term:
          id: CL:0000129
          label: microglial cell
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Magnetic resonance imaging showed improvement in cochlear
          and leptomeningeal lesions as compared with baseline."
        explanation: MRI documentation of cochlear and leptomeningeal
          inflammatory lesions in NOMID patients, which improved with
          anakinra treatment, confirming active CNS inflammation.
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Among these novel mutations, percentages of severe
          musculoskeletal, ophthalmologic, and neurological symptoms were
          higher compared with other case serials."
        explanation: Large pediatric CAPS cohort showing high prevalence of
          severe neurological symptoms in patients with novel NLRP3
          mutations, consistent with the CNS inflammatory burden in
          CINCA/NOMID.
  - name: Epiphyseal skeletal overgrowth
    description: >
      IL-1beta-driven inflammation at the growth plates stimulates
      abnormal endochondral ossification, producing characteristic
      bony overgrowth of the patellae, distal femora, and other long
      bone epiphyses. The distinctive radiographic features include
      epiphyseal enlargement and calcified physeal lesions unique
      to CINCA/NOMID within the CAPS spectrum.
    locations:
      - preferred_term: Epiphysis
        term:
          id: UBERON:0001437
          label: epiphysis
      - preferred_term: Growth plate cartilage
        term:
          id: UBERON:0004129
          label: growth plate cartilage
    biological_processes:
      - preferred_term: Endochondral ossification
        term:
          id: GO:0001958
          label: endochondral ossification
        modifier: ABNORMAL
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Ten patients received Canakinumab treatment, which proved
          effective at alleviating musculoskeletal, neurological, auditory,
          visual manifestations, fever, and rash for 10-20 months
          follow-up."
        explanation: Pediatric CAPS cohort documenting musculoskeletal
          involvement as a major disease domain responsive to IL-1
          blockade, confirming IL-1-driven skeletal overgrowth.
  - name: Cartilage damage and destructive arthropathy
    description: >
      Chronic IL-1beta-mediated inflammation in the joints drives
      chondrocyte dysfunction and cartilage matrix degradation,
      leading to progressive destructive arthropathy. Extracellular
      matrix disassembly in articular cartilage results in joint
      deformity and functional impairment distinctive to the severe
      CINCA/NOMID phenotype.
    locations:
      - preferred_term: Synovial joint
        term:
          id: UBERON:0002217
          label: synovial joint
    cell_types:
      - preferred_term: Chondrocyte
        term:
          id: CL:0000138
          label: chondrocyte
    biological_processes:
      - preferred_term: Extracellular matrix disassembly
        term:
          id: GO:0022617
          label: extracellular matrix disassembly
        modifier: ABNORMAL
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: Landmark NEJM trial identifying deforming arthropathy
          as a cardinal feature of NOMID/CINCA, distinct from bony
          overgrowth and reflecting cartilage destruction.
  - name: Secondary amyloidosis
    description: >
      Chronic uncontrolled systemic inflammation leads to sustained
      elevation of serum amyloid A (SAA), which can deposit as AA
      amyloid in kidneys and other organs. This potentially causes
      nephrotic syndrome and renal failure if untreated. AA amyloidosis
      is a recognized long-term complication across the CAPS spectrum,
      particularly in undertreated patients.
    locations:
      - preferred_term: Kidney
        term:
          id: UBERON:0002113
          label: kidney
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "serum amyloid A (from a median of 174 mg to 8 mg per
          liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg
          per deciliter), and the erythrocyte sedimentation rate decreased
          at month 3"
        explanation: NEJM trial documenting markedly elevated baseline
          serum amyloid A levels (median 174 mg/L) in NOMID patients,
          reflecting the chronic inflammatory state that drives AA
          amyloidosis risk. SAA normalized rapidly with anakinra.
phenotypes:
  - name: Urticarial rash
    description: >
      Non-pruritic, migratory urticaria-like rash present from birth or
      the neonatal period. The rash is a neutrophilic urticarial
      dermatosis rather than mast cell-mediated urticaria, and worsens
      with cold exposure, fever, or stress. Present in virtually all
      CINCA/NOMID patients.
    frequency: OBLIGATE
    notes: >
      18/18 (100%) NOMID patients in the Goldbach-Mansky NEJM cohort
      had urticarial rash at baseline, supporting OBLIGATE frequency.
    context: Neonatal onset, persistent
    diagnostic: true
    phenotype_term:
      preferred_term: Urticaria
      term:
        id: HP:0001025
        label: Urticaria
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "All 18 patients had a rapid response to anakinra, with
          disappearance of rash."
        explanation: All 18 NOMID patients in the landmark NEJM trial had
          urticarial rash at baseline which resolved rapidly with anakinra,
          confirming universality and IL-1 dependence of this phenotype.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients most commonly presented with rash (100%),
          arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever
          (77.8%), and growth retardation (44.4%)."
        explanation: Chinese NLRP3-AID cohort of 9 patients confirming
          rash in 100% of cases, consistent with OBLIGATE frequency
          across different populations.
  - name: Recurrent fever
    description: >
      Recurrent or continuous low-grade fever beginning in the neonatal
      period, often accompanying flares of the urticarial rash. Fever
      is driven by systemic IL-1beta overproduction.
    frequency: VERY_FREQUENT
    notes: >
      Listed as a defining characteristic of NOMID; present in the
      majority of patients though not always continuous.
    context: Neonatal onset, often continuous rather than episodic
    phenotype_term:
      preferred_term: Recurrent fever
      term:
        id: HP:0001954
        label: Recurrent fever
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: NEJM trial establishing fever as a cardinal feature
          of NOMID/CINCA.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients most commonly presented with rash (100%),
          arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever
          (77.8%), and growth retardation (44.4%)."
        explanation: Chinese NLRP3-AID cohort showing fever in 77.8%
          of patients, consistent with VERY_FREQUENT classification.
  - name: Arthropathy with epiphyseal overgrowth
    description: >
      Ranges from arthralgia and joint swelling in milder cases to severe
      deforming arthropathy with characteristic bony overgrowth of the
      patellae, distal femora, and other epiphyses. The patellar
      overgrowth pattern is distinctive to CINCA/NOMID within the CAPS
      spectrum.
    frequency: VERY_FREQUENT
    notes: >
      Deforming arthropathy is a defining feature of NOMID; the
      distinctive epiphyseal overgrowth pattern distinguishes CINCA
      from milder CAPS phenotypes.
    context: Progressive, onset in infancy
    diagnostic: true
    phenotype_term:
      preferred_term: Arthropathy
      term:
        id: HP:0003040
        label: Arthropathy
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: NEJM trial identifying deforming arthropathy as a
          cardinal feature of NOMID/CINCA.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients most commonly presented with rash (100%),
          arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever
          (77.8%), and growth retardation (44.4%)."
        explanation: Chinese NLRP3-AID cohort showing arthritis/arthralgia
          in 88.9% (8/9) of patients, with two CINCA cases also having
          clubbed fingers.
  - name: Chronic aseptic meningitis
    description: >
      Chronic aseptic meningitis with elevated CSF pressure, pleocytosis,
      and elevated protein. Leads to headaches, papilledema, and
      progressive neurological damage including cognitive impairment.
      May cause ventriculomegaly, cerebral atrophy, macrocephaly, and
      rarely subdural hemorrhages.
    frequency: VERY_FREQUENT
    notes: >
      Aseptic meningitis is part of the diagnostic triad of NOMID and
      is present in the majority of patients; its chronicity
      distinguishes CINCA from the milder CAPS phenotypes.
    context: Chronic, from neonatal period
    severity: Severe
    diagnostic: true
    phenotype_term:
      preferred_term: Meningitis
      term:
        id: HP:0001287
        label: Meningitis
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: NEJM trial establishing chronic aseptic meningitis as
          a hallmark neurological manifestation of NOMID/CINCA.
      - reference: PMID:37548074
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "These, along with significant cerebral atrophy,
          ventriculomegaly, and an absence of other injuries, raised
          concerns for a genetic disorder, prompting genetic
          consultation."
        explanation: Case report of an infant with CINCA/NOMID presenting
          with subdural hemorrhage, macrocephaly, cerebral atrophy, and
          ventriculomegaly secondary to chronic CNS inflammation,
          initially raising suspicion of abusive head trauma.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "the examination of the cerebrospinal fluid (CSF) showed
          a WBC cell count of 667 /\u00b5L (polymorphonuclear: mononuclear
          4:1), glucose at 21 mg/dL, and protein at 191 mg/dL"
        explanation: Neonatal case documenting severe CSF pleocytosis
          (667 cells) with neutrophilic predominance, hypoglycorrhachia,
          and markedly elevated protein at birth, confirming
          intrauterine-onset aseptic meningitis.
  - name: Sensorineural hearing loss
    description: >
      Progressive sensorineural hearing loss developing in childhood,
      related to chronic cochlear inflammation and/or chronic meningitis.
      May progress to profound deafness without treatment. Cochlear
      lesions are visible on MRI and can improve with IL-1 blockade.
    frequency: VERY_FREQUENT
    notes: >
      Hearing loss is listed as a defining feature of NOMID; cochlear
      lesions were documented on MRI in the NEJM cohort and improved
      with anakinra.
    context: Progressive, childhood onset
    phenotype_term:
      preferred_term: Sensorineural hearing impairment
      term:
        id: HP:0000407
        label: Sensorineural hearing impairment
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Magnetic resonance imaging showed improvement in cochlear
          and leptomeningeal lesions as compared with baseline."
        explanation: NEJM trial documenting cochlear inflammatory lesions
          on MRI in NOMID patients that improved with anakinra, linking
          hearing loss to reversible cochlear inflammation.
  - name: Papilledema
    description: >
      Optic disc swelling due to elevated intracranial pressure from
      chronic aseptic meningitis. Can progress to optic atrophy and
      vision loss if untreated.
    frequency: VERY_FREQUENT
    context: Secondary to chronic meningitis
    phenotype_term:
      preferred_term: Papilledema
      term:
        id: HP:0001085
        label: Papilledema
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Among these novel mutations, percentages of severe
          musculoskeletal, ophthalmologic, and neurological symptoms were
          higher compared with other case serials."
        explanation: Large pediatric CAPS cohort confirming high prevalence
          of ophthalmologic involvement including papilledema in severe
          CAPS phenotypes.
  - name: Short stature
    description: >
      Growth retardation and short stature related to chronic systemic
      inflammation and skeletal abnormalities. Failure to thrive is
      common in untreated patients.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Short stature
      term:
        id: HP:0004322
        label: Short stature
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Neonatal-onset multisystem inflammatory disease is
          characterized by fever, urticarial rash, aseptic meningitis,
          deforming arthropathy, hearing loss, and mental retardation."
        explanation: NEJM description of NOMID encompassing growth
          retardation and developmental delay as part of the multisystem
          disease burden.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients most commonly presented with rash (100%),
          arthritis/arthralgia (88.9%), lymphadenopathy (88.9%), fever
          (77.8%), and growth retardation (44.4%)."
        explanation: Chinese NLRP3-AID cohort documenting growth
          retardation in 44.4% of patients, consistent with FREQUENT
          frequency classification.
      - reference: PMID:37548074
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "multidisciplinary evaluation identified multiple
          abnormalities, including rash, macrocephaly, growth failure, and
          elevated inflammatory markers, which were all atypical for
          trauma."
        explanation: Case report documenting growth failure as part of
          the clinical presentation of CINCA/NOMID in an infant.
  - name: Hepatosplenomegaly
    description: >
      Enlargement of the liver and spleen due to chronic systemic
      inflammation and reticuloendothelial activation. May be accompanied
      by cholestasis in severe neonatal cases, which can gradually
      improve with anti-inflammatory treatment.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Hepatosplenomegaly
      term:
        id: HP:0001433
        label: Hepatosplenomegaly
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Cryopyrin-associated periodic syndrome (CAPS) is a rare
          inherited autoinflammatory disorder characterized by systemic,
          cutaneous, musculoskeletal, and central nervous system
          inflammation."
        explanation: Review characterizing CAPS as a systemic inflammatory
          disorder with widespread organ involvement including
          hepatosplenomegaly from reticuloendothelial activation.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "She also exhibited atypical symptoms such as severe
          hepatosplenomegaly with cholestasis."
        explanation: Case report documenting severe hepatosplenomegaly with
          cholestasis as a neonatal manifestation of CINCA/NOMID,
          which gradually improved in parallel with decreasing
          inflammatory markers after canakinumab treatment.
  - name: Uveitis
    description: >
      Ocular inflammation affecting the uveal tract, which may present as
      anterior or posterior uveitis. Contributes to visual impairment
      alongside papilledema and optic atrophy.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Uveitis
      term:
        id: HP:0000554
        label: Uveitis
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Ten patients received Canakinumab treatment, which proved
          effective at alleviating musculoskeletal, neurological, auditory,
          visual manifestations, fever, and rash for 10-20 months
          follow-up."
        explanation: Pediatric cohort confirming visual manifestations
          (including uveitis) as a major disease domain in severe CAPS
          responsive to IL-1 blockade.
biochemical:
  - name: Serum amyloid A
    presence: ELEVATED
    context: Median 174 mg/L at baseline (normal <10 mg/L), normalizes with anakinra
    biomarker_term:
      preferred_term: Serum Amyloid A
      term:
        id: NCIT:C105940
        label: Serum Amyloid A
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "serum amyloid A (from a median of 174 mg to 8 mg per
          liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg
          per deciliter), and the erythrocyte sedimentation rate decreased
          at month 3"
        explanation: NEJM trial documenting markedly elevated baseline
          SAA (median 174 mg/L) in NOMID patients which normalized
          rapidly with anakinra, establishing SAA as a key disease
          activity biomarker.
  - name: C-reactive protein
    presence: ELEVATED
    context: Median 5.29 mg/dL at baseline, normalizes with anakinra
    biomarker_term:
      preferred_term: C-Reactive Protein
      term:
        id: NCIT:C60651
        label: C-Reactive Protein
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "serum amyloid A (from a median of 174 mg to 8 mg per
          liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg
          per deciliter), and the erythrocyte sedimentation rate decreased
          at month 3"
        explanation: NEJM trial documenting elevated CRP (median 5.29
          mg/dL) in NOMID patients which decreased to 0.34 mg/dL with
          anakinra, confirming CRP as a reliable inflammatory marker.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "During acute attack, white blood cell, C-reactive protein,
          and/or erythrocyte sedimentation rate all increased in all cases,
          and inflammatory markers remained elevated beyond 7 days
          postfever resolution in 57.1% of patients (4/7)."
        explanation: Chinese cohort confirming universal CRP elevation
          during flares in NLRP3-AID patients, with persistent elevation
          in over half of patients even after fever resolution.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The blood examination at birth revealed CRP at 6.4 mg/dL"
        explanation: Neonatal case documenting markedly elevated CRP
          (6.4 mg/dL, rising to 15 mg/dL) at birth despite absence
          of infection, confirming intrauterine inflammatory activation.
  - name: Erythrocyte sedimentation rate
    presence: ELEVATED
    context: Markedly elevated, normalizes with anakinra
    biomarker_term:
      preferred_term: Erythrocyte Sedimentation Rate Measurement
      term:
        id: NCIT:C74611
        label: Erythrocyte Sedimentation Rate Measurement
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "serum amyloid A (from a median of 174 mg to 8 mg per
          liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg
          per deciliter), and the erythrocyte sedimentation rate decreased
          at month 3"
        explanation: NEJM trial documenting elevated ESR in NOMID
          patients which decreased with anakinra at month 3 and
          remained low at month 6.
      - reference: PMID:38481988
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "During acute attack, white blood cell, C-reactive protein,
          and/or erythrocyte sedimentation rate all increased in all cases"
        explanation: Chinese cohort confirming universal ESR elevation
          during acute attacks across all 9 NLRP3-AID patients.
diagnosis:
  - name: Clinical assessment
    description: >
      Diagnosis is suspected based on the triad of neonatal-onset
      urticarial rash, chronic meningitis, and arthropathy. Elevated
      acute phase reactants (ESR, CRP, serum amyloid A) and
      leukocytosis with neutrophilia support the diagnosis. CSF
      analysis shows aseptic meningitis with pleocytosis.
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Diary scores improved (P<0.001) and serum amyloid A (from
          a median of 174 mg to 8 mg per liter), C-reactive protein (from
          a median of 5.29 mg to 0.34 mg per deciliter), and the
          erythrocyte sedimentation rate decreased at month 3"
        explanation: NEJM trial quantifying the characteristic laboratory
          abnormalities in NOMID (markedly elevated SAA, CRP, ESR) that
          support clinical diagnosis and serve as biomarkers for disease
          activity.
  - name: Genetic testing for NLRP3 mutations
    description: >
      Confirmatory diagnosis by identification of heterozygous
      gain-of-function NLRP3 mutations. Standard Sanger sequencing
      detects mutations in approximately 50-60% of cases. Deep
      sequencing or next-generation sequencing can detect somatic
      mosaicism with variant allele fractions as low as 1.3% in
      some mutation-negative cases. Clinical diagnosis should not be
      delayed pending genetic confirmation when the clinical picture
      is highly suggestive.
    diagnosis_term:
      preferred_term: genetic testing
      term:
        id: MAXO:0000127
        label: genetic testing
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients harbored 19 substitutions in NLRP3, and 8 of
          them were novel mutations."
        explanation: Large pediatric CAPS cohort identifying 19 NLRP3
          variants including 8 novel mutations through genetic testing,
          with functional confirmation via inflammasome activation assays.
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "we screened exons in the 1q44 region for mutations by
          direct sequencing of genomic DNA from affected individuals and
          controls. This resulted in the identification of four distinct
          mutations in a gene that segregated with the disorder"
        explanation: Original gene identification study establishing
          sequencing of CIAS1/NLRP3 as the definitive diagnostic test
          for CAPS.
      - reference: PMID:38720945
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "this case highlights the importance of early diagnosis of
          CINCA patients when the clinical and laboratory picture is highly
          suggestive in order to start the appropriate anti-cytokine
          treatment even in the absence of a genetic confirmation."
        explanation: Case report emphasizing that treatment should not be
          withheld pending genetic confirmation, as initial testing may
          miss somatic mosaicism detectable only by advanced sequencing.
      - reference: PMID:37548074
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Clinical trio exome sequencing identified a de novo likely
          pathogenic variant in NLRP3, which is associated with chronic
          infantile neurological, cutaneous, and articular (CINCA)
          syndrome"
        explanation: Case illustrating the diagnostic utility of trio
          exome sequencing in identifying de novo NLRP3 variants,
          especially when clinical presentation initially mimics
          other conditions such as abusive head trauma.
treatments:
  - name: IL-1 inhibition with anakinra
    description: >
      Anakinra (recombinant IL-1 receptor antagonist) is the first-line
      treatment. Daily subcutaneous injections rapidly suppress
      inflammation, rash, fever, and normalize inflammatory markers.
      Early treatment can prevent or stabilize neurological damage
      including hearing loss, cognitive impairment, and papilledema.
      MRI-visible cochlear and leptomeningeal lesions improve with
      treatment.
    context: First-line therapy
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: Therapeutic Agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: Anakinra
            term:
              id: NCIT:C38717
              label: Anakinra
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
      - preferred_term: Urticaria
        term:
          id: HP:0001025
          label: Urticaria
    evidence:
      - reference: PMID:16899778
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "All 18 patients had a rapid response to anakinra, with
          disappearance of rash. Diary scores improved (P<0.001) and serum
          amyloid A (from a median of 174 mg to 8 mg per liter), C-reactive
          protein (from a median of 5.29 mg to 0.34 mg per deciliter), and
          the erythrocyte sedimentation rate decreased at month 3
          (all P<0.001), and remained low at month 6."
        explanation: Landmark NEJM trial of 18 NOMID patients demonstrating
          rapid and sustained response to anakinra with normalization of
          inflammatory markers and improvement of MRI-documented cochlear
          and leptomeningeal lesions.
      - reference: PMID:38720945
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "After a 12-year follow-up, the patient has not experienced
          chronic complications."
        explanation: Case report demonstrating that early initiation of
          IL-1 inhibition (anakinra followed by canakinumab) in a CINCA
          patient with somatic mosaicism prevented development of chronic
          sequelae over 12 years of follow-up.
  - name: IL-1 inhibition with canakinumab
    description: >
      Canakinumab (anti-IL-1beta monoclonal antibody) provides sustained
      IL-1 blockade with less frequent dosing (every 4-8 weeks
      subcutaneously). Effective for long-term disease control across
      musculoskeletal, neurological, auditory, and visual domains in
      CINCA/NOMID.
    context: Long-acting IL-1 blockade
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: Therapeutic Agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: Canakinumab
            term:
              id: NCIT:C80971
              label: Canakinumab
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
      - preferred_term: Arthropathy
        term:
          id: HP:0003040
          label: Arthropathy
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Ten patients received Canakinumab treatment, which proved
          effective at alleviating musculoskeletal, neurological, auditory,
          visual manifestations, fever, and rash for 10-20 months
          follow-up."
        explanation: Pediatric CAPS cohort demonstrating canakinumab
          efficacy across multiple organ domains over 10-20 months,
          while non-IL-1 therapies achieved only partial remission.
      - reference: PMID:34059097
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "treatment with recombinant anti- human IL-1\u03b2 monoclonal
          antibody (canakinumab) was started at a dose of 2.5 mg/kg. The
          rash immediately disappeared, and inflammatory markers slightly
          decreased after the first administration."
        explanation: Neonatal case demonstrating rapid clinical response
          to canakinumab at 70 days of age, with immediate rash
          disappearance and gradual improvement of cholestasis, supporting
          early canakinumab use in severe neonatal CINCA.
  - name: IL-1 inhibition with rilonacept
    description: >
      Rilonacept (IL-1 Trap, a soluble decoy receptor) is another IL-1
      inhibitor approved for CAPS. Administered weekly by subcutaneous
      injection. Captures both IL-1alpha and IL-1beta.
    context: Alternative IL-1 blockade
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: Therapeutic Agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: Rilonacept
            term:
              id: NCIT:C84137
              label: Rilonacept
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Investigators have taken advantage of some of these
          pathways to develop and apply novel targeted therapies, which
          have resulted in improved quality of life for patients with this
          orphan disease."
        explanation: Review describing the development and application of
          IL-1 targeted therapies including rilonacept for CAPS patients.
  - name: Genetic counseling
    description: >
      Genetic counseling is recommended for affected families. Most
      CINCA/NOMID cases arise from de novo mutations, but germline
      transmission is possible. Assessment of recurrence risk, somatic
      mosaicism implications, and reproductive options should be
      discussed.
    treatment_term:
      preferred_term: genetic counseling
      term:
        id: MAXO:0000079
        label: genetic counseling
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "This resulted in the identification of four distinct
          mutations in a gene that segregated with the disorder in three
          families with FCAS and one family with MWS."
        explanation: Original identification of CIAS1/NLRP3 mutations
          segregating in families, establishing the basis for genetic
          counseling about inheritance patterns in CAPS.
prevalence:
  - population: General population
    notes: >
      CINCA/NOMID is extremely rare, with an estimated prevalence of
      less than 1 per 1,000,000. It is the most severe phenotype within
      the CAPS spectrum.
    evidence:
      - reference: PMID:31077002
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Cryopyrin-associated periodic syndrome (CAPS) is a rare
          inherited autoinflammatory disorder characterized by systemic,
          cutaneous, musculoskeletal, and central nervous system
          inflammation."
        explanation: Review establishing CAPS as a rare inherited disorder,
          with CINCA/NOMID representing the most severe and rarest end
          of the spectrum.
genetic:
  - name: NLRP3
    gene_term:
      preferred_term: NLRP3
      term:
        id: hgnc:16400
        label: NLRP3
    association: Causative
    notes: >
      Caused by heterozygous gain-of-function mutations in NLRP3 (also
      known as CIAS1 or NALP3), encoding cryopyrin. Over 170
      disease-associated NLRP3 variants have been reported across the
      CAPS spectrum. Most CINCA mutations are de novo. Somatic mosaicism
      with variant allele fractions as low as 1.3% is present in a
      subset of mutation-negative cases.
    presence: PRESENT
    inheritance:
      - name: Autosomal dominant
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "This resulted in the identification of four distinct
          mutations in a gene that segregated with the disorder in three
          families with FCAS and one family with MWS."
        explanation: Original identification of CIAS1/NLRP3 as the
          causative gene for CAPS by Hoffman et al. 2001.
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The patients harbored 19 substitutions in NLRP3, and 8 of
          them were novel mutations."
        explanation: Large pediatric cohort expanding the NLRP3 mutation
          spectrum with 8 novel variants, including documentation of
          somatic mosaicism (F311V).
inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    penetrance: COMPLETE
    expressivity: VARIABLE
    de_novo_rate: ">80"
    description: >
      CINCA syndrome follows autosomal dominant inheritance with
      complete penetrance but variable expressivity across the CAPS
      spectrum. The majority of cases (>80%) arise from de novo
      mutations. Somatic mosaicism is recognized in a subset of
      clinically affected individuals who test negative by
      conventional sequencing, with variant allele fractions ranging
      from 1.3% to 34.8%.
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Familial cold autoinflammatory syndrome (FCAS, MIM
          120100), commonly known as familial cold urticaria (FCU), is an
          autosomal-dominant systemic inflammatory disease"
        explanation: Original study establishing autosomal dominant
          inheritance for the CAPS spectrum caused by CIAS1/NLRP3
          mutations.
      - reference: PMID:38808101
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The father carried a genetic mutation associated with
          CINCA syndrome/NOMID (NLRP3 c.2068G>A p.Glu690Lys Hetero),
          which was also found in the child."
        explanation: Case documenting paternal transmission of NLRP3
          mutation to a child with CINCA/NOMID, confirming autosomal
          dominant inheritance in the minority of familial (non-de novo)
          cases.
environmental:
  - name: Cold exposure
    description: >
      Cold temperatures can trigger or exacerbate disease flares,
      including urticarial rash, fever, and joint symptoms. This is
      a shared feature across the CAPS spectrum, though in CINCA/NOMID
      symptoms are often continuous rather than purely cold-triggered.
    effect: TRIGGERING
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Familial cold autoinflammatory syndrome (FCAS, MIM
          120100), commonly known as familial cold urticaria (FCU), is an
          autosomal-dominant systemic inflammatory disease characterized by
          intermittent episodes of rash, arthralgia, fever and
          conjunctivitis after generalized exposure to cold."
        explanation: Original gene identification paper establishing cold
          exposure as a trigger across the CAPS spectrum, with FCAS
          being the most cold-sensitive phenotype.
differential_diagnoses:
  - name: Muckle-Wells syndrome
    description: >
      Another CAPS phenotype caused by NLRP3 mutations but with
      intermediate severity. Presents with urticarial rash, episodic
      fever, arthralgia, and progressive sensorineural hearing loss,
      but lacks the chronic meningitis and bony overgrowth
      characteristic of CINCA/NOMID.
    disease_term:
      preferred_term: Muckle-Wells syndrome
      term:
        id: MONDO:0008633
        label: Muckle-Wells syndrome
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Muckle-Wells syndrome (MWS; MIM 191900), which also maps
          to chromosome 1q44, is an autosomal-dominant periodic fever
          syndrome with a similar phenotype except that symptoms are not
          precipitated by cold exposure and that sensorineural hearing loss
          is frequently also present."
        explanation: Original description of MWS sharing the NLRP3 genetic
          basis with FCAS, establishing the CAPS spectrum and the need
          to differentiate MWS from CINCA/NOMID by severity.
  - name: Familial cold autoinflammatory syndrome
    description: >
      The mildest CAPS phenotype, presenting with cold-triggered
      urticarial episodes, fever, and arthralgia lasting less than 24
      hours. No neurological or skeletal involvement. Also caused by
      NLRP3 mutations.
    disease_term:
      preferred_term: Familial cold autoinflammatory syndrome 1
      term:
        id: MONDO:0007349
        label: familial cold autoinflammatory syndrome 1
    evidence:
      - reference: PMID:11687797
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Familial cold autoinflammatory syndrome (FCAS, MIM
          120100), commonly known as familial cold urticaria (FCU), is an
          autosomal-dominant systemic inflammatory disease characterized by
          intermittent episodes of rash, arthralgia, fever and
          conjunctivitis after generalized exposure to cold."
        explanation: Original identification of CIAS1/NLRP3 mutations in
          FCAS families, establishing it as the mildest CAPS phenotype
          distinguished from CINCA by episodic cold-triggered symptoms
          only.
  - name: Systemic juvenile idiopathic arthritis
    description: >
      Presents with quotidian fever, evanescent rash, and arthritis in
      childhood. Distinguished from CINCA by age of onset (typically
      after 6 months), different rash character (evanescent
      salmon-colored rather than persistent neutrophilic urticaria),
      absence of chronic meningitis and bony overgrowth, and negative
      NLRP3 genetic testing.
    disease_term:
      preferred_term: Juvenile idiopathic arthritis
      term:
        id: MONDO:0011429
        label: juvenile idiopathic arthritis
    evidence:
      - reference: PMID:37809096
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Patients treated with prednisolone or prednisolone plus
          thalidomide or methotrexate, tocilizumab, TNF inhibiting agents,
          and sirolimus achieved only partial remission."
        explanation: Pediatric cohort showing that non-IL-1 therapies
          commonly used for systemic JIA (prednisolone, methotrexate,
          tocilizumab) achieved only partial remission in CAPS, helping
          to distinguish CINCA from sJIA by differential treatment
          response.
datasets:
  - accession: geo:GSE43553
    title: >
      Microarray-based gene expression profiling in patients with
      cryopyrin-associated periodic syndromes defines a disease-related
      signature and IL-1-responsive transcripts
    description: >-
      Gene expression microarray profiling of 16 CAPS patients before
      and after anakinra treatment, compared to healthy controls. Defines
      a CAPS-specific gene expression signature including transcripts
      related to innate and adaptive immune responses, oxidative stress,
      cell death, and cell adhesion.
    organism:
      preferred_term: human
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: MICROARRAY
    sample_types:
      - preferred_term: peripheral blood
        tissue_term:
          preferred_term: blood
          term:
            id: UBERON:0000178
            label: blood
    sample_count: 100
    conditions:
      - CAPS patients pre-treatment
      - CAPS patients post-anakinra
      - healthy controls
    evidence:
      - reference: GEO:GSE43553
        supports: SUPPORT
        snippet: "We identified a gene expression signature that clearly
          distinguished CAPS patients from controls. A number of DEG were
          in common with other systemic inflammatory diseases such as
          systemic onset juvenile idiopathic arthritis."
        explanation: Defines a CAPS-specific transcriptomic signature and
          identifies IL-1-responsive genes, relevant to understanding
          the molecular pathology of CINCA/NOMID.
  - accession: geo:GSE38626
    title: >
      Induced pluripotent stem cells from CINCA syndrome patients as a
      model for dissecting somatic mosaicism and drug discovery
    description: >-
      iPSC lines generated from two CINCA syndrome patients with somatic
      NLRP3 mosaicism, differentiated into macrophages. Demonstrates
      that mutant iPSC-derived macrophages show abnormal IL-1beta
      secretion and can serve as a drug screening platform.
    organism:
      preferred_term: human
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: MICROARRAY
    sample_count: 15
    conditions:
      - NLRP3-mutant iPSC-derived macrophages
      - non-mutant iPSC-derived macrophages
    evidence:
      - reference: GEO:GSE38626
        supports: SUPPORT
        snippet: "We found that mutant cells are predominantly responsible
          for the pathogenesis in these mosaic patients because only mutant
          iPS-MPs showed the disease relevant phenotype of abnormal IL-1
          secretion."
        explanation: Directly relevant to CINCA somatic mosaicism
          pathogenesis, demonstrating that NLRP3-mutant cells drive the
          inflammatory phenotype and providing a platform for drug
          discovery.
clinical_trials:
  - name: NCT00069329
    description: >
      NIH-sponsored long-term study evaluating anakinra (Kineret) for
      NOMID/CINCA syndrome. This landmark trial demonstrated rapid and
      sustained efficacy of IL-1 receptor antagonism for controlling
      systemic inflammation, rash, fever, and CNS disease.
    phase: PHASE_II
    status: TERMINATED
    target_phenotypes:
      - preferred_term: Urticaria
        term:
          id: HP:0001025
          label: Urticaria
      - preferred_term: Meningitis
        term:
          id: HP:0001287
          label: Meningitis
      - preferred_term: Arthropathy
        term:
          id: HP:0003040
          label: Arthropathy
      - preferred_term: Papilledema
        term:
          id: HP:0001085
          label: Papilledema
    evidence:
      - reference: clinicaltrials:NCT00069329
        supports: SUPPORT
        snippet: "This study will evaluate the safety and effectiveness
          of anakinra (Kineret) for treating patients with
          neonatal-onset multisystem inflammatory disease (NOMID), also
          known as chronic infantile neurological, cutaneous and
          arthropathy (CINCA) syndrome."
        explanation: Landmark NIH trial establishing anakinra as
          effective therapy for NOMID/CINCA, forming the basis for
          the published NEJM results (PMID:16899778).
  - name: NCT00770601
    description: >
      Multi-center, open-label, 24-month study evaluating canakinumab
      (anti-IL-1beta antibody) safety, tolerability, efficacy, and
      pharmacokinetics specifically in NOMID/CINCA patients aged 2 years
      and older. Included lumbar puncture, MRI, and cognitive evaluations.
    phase: PHASE_III
    status: TERMINATED
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
      - preferred_term: Urticaria
        term:
          id: HP:0001025
          label: Urticaria
      - preferred_term: Meningitis
        term:
          id: HP:0001287
          label: Meningitis
    evidence:
      - reference: clinicaltrials:NCT00770601
        supports: SUPPORT
        snippet: "This study will examine whether a medicine called
          canakinumab is safe and effective for treating patients with
          neonatal-onset multisystem inflammatory disease (NOMID), also
          known as chronic infantile neurologic, cutaneous, articular
          (CINCA) syndrome."
        explanation: NOMID/CINCA-specific canakinumab trial with
          comprehensive CNS outcome measures including lumbar puncture
          and MRI.
  - name: NCT00685373
    description: >
      Open-label, long-term safety and efficacy study of canakinumab
      (ACZ885) in patients with CAPS including NOMID. Subcutaneous
      injection for at least 6 months with extension up to 2 years.
    phase: PHASE_III
    status: COMPLETED
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
      - preferred_term: Urticaria
        term:
          id: HP:0001025
          label: Urticaria
    evidence:
      - reference: clinicaltrials:NCT00685373
        supports: SUPPORT
        snippet: "newly identified patients with the following
          cryopyrin-associated periodic syndromes: Familial Cold
          Autoinflammatory Syndrome, Muckle-Wells Syndrome or Neonatal
          Onset Multisystem Inflammatory Disease."
        explanation: Long-term canakinumab safety and efficacy data in
          CAPS patients including those with NOMID.
  - name: NCT01302860
    description: >
      One-year open-label trial of canakinumab in pediatric CAPS
      patients aged 4 years and younger, including those with NOMID.
      Also evaluated safety of childhood vaccinations during canakinumab
      treatment.
    phase: PHASE_III
    status: COMPLETED
    target_phenotypes:
      - preferred_term: Recurrent fever
        term:
          id: HP:0001954
          label: Recurrent fever
      - preferred_term: Urticaria
        term:
          id: HP:0001025
          label: Urticaria
    evidence:
      - reference: clinicaltrials:NCT01302860
        supports: SUPPORT
        snippet: "This trial will assess the safety, efficacy and
          tolerability of ACZ885 in patients aged 4 years and younger
          with cryopyrin associated periodic syndromes (CAPS)"
        explanation: Pediatric-focused canakinumab trial relevant to
          CINCA/NOMID given its neonatal onset and need for early
          treatment.
  - name: NCT02974595
    description: >
      NIH natural history study of autoinflammatory diseases including
      NOMID/CAPS, with long-term follow-up up to 15 years. Evaluates
      clinical outcomes, pathogenesis, genetic causes, and treatment
      responses across the autoinflammatory disease spectrum.
    phase: NOT_APPLICABLE
    status: RECRUITING
    evidence:
      - reference: clinicaltrials:NCT02974595
        supports: SUPPORT
        snippet: "Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI,
          NLRC4-MAS, Still's Disease, and with other yet
          undifferentiated autoinflammatory diseases."
        explanation: Ongoing NIH natural history study providing
          longitudinal data on NOMID/CAPS disease course, outcomes,
          and treatment responses.
